[Peptide bioregulators: delivery and efficacy]. / Peptidnye bioregulyatory: sposob vvedeniya i effektivnost'.

PURPOSE: To compare the neuroprotective properties of retinalamin administered in different ways among open-angle glaucoma patients with compensated intraocular pressure. MATERIAL AND METHODS: The study included 498 patients (eyes) with initial, moderate and advanced stages of glaucoma. Patients were divided into 3 groups: group I (n=110) received 5 mg intramuscular and 5 mg retrobulbar injections of retinalamin; group II (n=171) received 5 mg retrobulbar injection of retinalamin; group III received 5 mg intramuscular injection of retinalamin. The overall treatment dose contained 50 mg of retinalamin. All the patients underwent tonometry and static perimetry. Patients of group II with initial glaucoma and patients of group III with moderate glaucoma also underwent contrast sensitivity tests. The examinations were conducted before the treatment, and on months 3 and 6. RESULTS: Visual acuity did not change significantly. In group I, after 3 months of treatment total threshold retinal sensitivity increased by 122 dB in patients with initial glaucoma, by 166 dB in moderate and by 124 dB in advanced glaucoma. Positive trend was observed in patients with initial and moderate stages of glaucoma by month 6. In group II, total threshold retinal sensitivity increased by 123 dB in initial glaucoma and by 110 dB in moderate; the result did not change by month 6. No significant changes were observed in patients with advanced glaucoma. In group III, total threshold retinal sensitivity increased by 142 dB in initial glaucoma, by 274 dB in moderate and by 148 dB in advanced glaucoma. Regression began on the sixth month. In group II, patients with initial glaucoma were observed to have decreased sensorimotor reaction times to achromatic stimuli within the studied areas of central visual field. In group III, patients with advanced glaucoma were also observed to have decreased sensorimotor reaction times to achromatic stimuli detected within 1° and 5° areas from the fixation point, but not in the 10° area. CONCLUSION: Retinalamin is most effective in initial and moderate glaucoma stages. Intramuscular, retrobulbar and combined administration methods have comparable efficacy.

[A model of primary open-angle glaucoma: manifestations and outcomes].

OBJECTIVE: To determine the expected duration of the disease and the age of the patients with different stages ofprimary open-angle glaucoma complicated by pseudoexfoliation syndrome (PES) and/or patients with pseudoexfoliation glaucoma (PEG). METHODS: The study protocol included data from 120 patients (50 males (41.7%), 70 females (58.3%)); 189 eyes; 102 right eyes; 87 left eyes). The first study group (28 patients, 44 eyes) comprised patients with suspected glaucoma. The second group (53 patients, 84 eyes) consisted ofpatients with early glaucoma. The third group (21 patient, 33 eyes) included patients with advanced glaucoma, the forth group (18 patients, 28 eyes) comprised patients with terminal glaucoma. Mean age of the patients at diagnosis was 61.6 (58.4; 66.9) years and 66.9 (63.4; 72.8) years at the endpoint visit in 2013. In all cases, diagnosis was made in accordance with the differential diagnostics system and confirmed by special diagnostic techniques. The database included data from 3 qualified examinations taking account of the results of tonometry and static automated perimetry. RESULTS: The mean expected age of the patients age at the onset of blindness was 75.1 years. The occurrence of the event was limited to a period of 6.1 years. Mean age at the time of possible glaucoma development was 59.58 (56.14; 64.36) years. The disease itself could develop within 3.24 (-5.38; -1.2) years prior to diagnosis. CONCLUSION: Studies for glaucoma diagnosis should be focused on the age group of 55-60 years. The degree of IOP reduction in patients with advanced glaucoma does not agree with the Russian glaucoma society recommendations which accounts for progression of the disease.

[Markers of Fas-mediated apoptosis in primary open-angle glaucoma and opportunities of their pharmacological correction].

In order to assess the role of apoptosis in pathogenesis of primary open-angle glaucoma (POAG) apoptosis markers were studied in blood serum and tear fluid of patients with or suspected to have different stages glaucoma. To date the study of POAC pathogenesis goes along with search of possible ways of pharmacotherapy, neuroprotection is considered to be a promising option. Dynamics of sFas/Apo-1 and sFasL as the markers of Fas-mediated apoptosis was studied during treatment. We used nootropic citicoline as a neuroprotector. The markers were studied using enzyme immunoassay. The results show association of POAG onset and progression with interruption of Fas-mediated apoptosis, indicated by the level and proportion of sFas/Apo-1 and sFasL in tear fluid and in a less degree in blood serum. Characteristic features are detected in Fas/FasL system associated with glaucoma stage and correlating with some clinical and functional parameters (perimetry) that is important for understanding of POAG pathogenesis and for prognosis of disease course.